Surrozen Inc Aktie News

SOUTH SAN FRANCISCO, Calif., 08. Sept. 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen oder das Unternehmen) (Nasdaq: SRZN), ein Biotechnologieunternehmen, das zielgerichtete Therapeutika entwickelt, um die Kraft der Wnt-Signalgebung zu nutzen und die zugrundeliegenden Treiber von Erkrankungen bei sehbedrohlichen ophthalmologischen Erkrankungen zu adressieren, gab heute die Einreichung eines ...

Geplante IND-Einreichung für SZN-8141 bei diabetischem Makulaödem bis Ende des dritten Quartals 2026 Erwartung, die SZN-8141 Phase‑1b/2a-Studie DUET bis Jahresende 2026 zu initiieren, mit ersten Daten voraussichtlich in der zweiten Hälfte 2027 Das U.S. Patent Trial and Appeal Board lehnt die Einleitung einer Post‑Grant-Review-Petition zur Anfechtung eines Surrozen-Patents ab SOUTH SAN FRANCISCO...

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor co...

On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of ...

SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option fo...

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ...